ABUSArbutus Biopharma Corp
Pharmaceutical Preparations
- Revenue
- $14M
- 128% YoY
- Operating margin
- -271.0%
- 78% YoY
- EBITDA
- −$38M
- 50% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$19M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired49% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $11M | $39M | $18M | $6M | $14M | 128% |
| Operating income | −$74M | −$65M | −$78M | −$76M | −$38M | 50% |
| Net income | −$76M | −$69M | −$73M | −$70M | −$34M | 52% |
| Operating cash flow | −$68M | −$35M | −$86M | −$65M | −$40M | 39% |
| Capex | $809K | $512K | $1M | $182K | $0 | 100% |
| Stock-based comp | $6M | $7M | $9M | $9M | $7M | 23% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 206 | — |
| FY2024 | — | — | 140 | — |
| FY2023 | — | — | 107 | — |